The Fostair Family

The only extrafine formulation ICS/LABA combination available in a range of devices and strengths^1–5

Designed to reach the large and small airways^1–4,6

2 devices, 2 strengths, 2 indications^1–4

• Fostair 100/6 is indicated for adult asthma and COPD (FEV₁ <50% predicted normal)^1,3
• Fostair 100/6 can also be used for Maintenance and Reliever Therapy (MART) for asthma in adults^1,3
• Fostair 200/6 is indicated for asthma in adults^2,4

The only ICS/LABA fixed-dose combination licensed in asthma and COPD in both pressurised metered dose inhalers (pMDI) and dry powder inhalers (DPI).^1,3

Fostair is indicated in the regular treatment of asthma in adults where use of a combination product (inhaled corticosteroid and long-acting β₂-agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂-agonist or patients already adequately controlled on both inhaled corticosteroids and long-acting β₂-agonist.^1-4

Fostair MART (100/6 ONLY) should especially be considered for patients with not fully controlled asthma and in need of reliever medication, patients with asthma exacerbations in the past requiring medical intervention.^1,3

Fostair 100/6 is indicated for symptomatic treatment of patients with severe COPD (FEV₁ <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.^1,3